Wenhao O. Ouyang et al.. High-throughput synthesis and specificity characterization of natively paired influenza hemagglutinin antibodies with oPool+ display. Sci Transl Med . 2025 Sep 3;17(814):eadt4147
Antibody discovery is crucial for developing therapeutics and vaccines and for understanding adaptive immunity. However, the lack of approaches to synthesize antibodies with defined sequences in a high-throughput manner represents a major bottleneck in antibody discovery. Here, we present oPool+ display, a high-throughput cell-free platform that combined oligo pool synthesis and mRNA display to rapidly construct and characterize hundreds to thousands of natively paired antibodies in parallel. As a proof of concept, we applied oPool+ display to probe the binding specificity of more than 300 uncommon influenza hemagglutinin-specific antibodies against nine hemagglutinin variants through 16 screens. More than 5000 binding tests were performed in 3 to 5 days of hands-on time with further scaling potential. Follow-up structural and functional analysis of two antibodies revealed the versatility of the human immunoglobulin gene segment D3-3 (IGHD-3-3) in recognizing the hemagglutinin stem. Overall, this study established an experimental platform that not only accelerates antibody characterization but also enables unbiased discovery of recurring molecular signatures among antibodies with the same specificity.
See Also:
Latest articles in those days:
- Weekly US Influenza Surveillance Report: Key Updates for Week 45, ending November 14, 2026 12 hours ago
- Anatomical Compartmentalization in Chickens Drives Divergent H9N2 Influenza Evolution Toward Human Receptor Binding and Immune Escape 1 days ago
- Epidemiologic Variability and Clinical Severity Across 11 Influenza Seasons in Children 2 days ago
- Molecular Epidemiology of Clade 2.3.4.4b H5N1 High-Pathogenicity Avian Influenza in South Africa, 2025-2026 2 days ago
- Structural basis of avian-to-human receptor-binding adaptation in H9Ny influenza A virus hemagglutinin 2 days ago
[Go Top] [Close Window]


